ORIC

8.56

0.71% 0.06

Dopo l'orario di chiusura: 8.56

Oric Pharmaceuticals Inc (ORIC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$8.50

Aprire:

$8.51

Volume 24 ore:

563.73K

Relative Volume:

1.28

Capitalizzazione di mercato:

$603.84M

Reddito:

Utile/perdita netta:

$-100.70M

Rapporto P/E:

-3.9266

EPS:

-2.18

Flusso di cassa netto:

$-86.54M

1 W Prestazione:

-16.89%

1M Prestazione:

-9.42%

6M Prestazione:

-6.55%

1 anno Prestazione:

+25.15%

Intervallo 1D:

$8.1225

$8.805

Intervallo di 1 settimana:

$8.105

$11.11

Portata 52W:

$6.33

$16.65

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Nome

Oric Pharmaceuticals Inc

Settore

Healthcare (1196)

Industria

Biotechnology (683)

Telefono

(650) 388-5600

Indirizzo

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Dipendente

112

Cinguettio

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

ORIC's Discussions on Twitter

Confronta ORIC con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ORIC	8.56	603.84M	0	-100.70M	-86.54M	-2.18
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-09-22	Iniziato	Wedbush	Outperform
2023-03-23	Aggiornamento	H.C. Wainwright	Neutral → Buy
2023-03-21	Aggiornamento	Guggenheim	Neutral → Buy
2023-03-16	Aggiornamento	Oppenheimer	Perform → Outperform
2022-07-18	Ripresa	Oppenheimer	Perform
2022-04-04	Aggiornamento	Citigroup	Neutral → Buy
2022-03-25	Downgrade	H.C. Wainwright	Buy → Neutral
2022-03-22	Downgrade	Citigroup	Buy → Neutral
2022-03-22	Downgrade	Guggenheim	Buy → Neutral
2022-03-22	Downgrade	Oppenheimer	Outperform → Perform
2021-07-06	Aggiornamento	Citigroup	Neutral → Buy
2021-01-25	Downgrade	Citigroup	Buy → Neutral
2020-08-13	Iniziato	Robert W. Baird	Outperform
2020-08-06	Aggiornamento	Citigroup	Neutral → Buy
2020-08-03	Iniziato	H.C. Wainwright	Buy
2020-05-19	Iniziato	Citigroup	Neutral
2020-05-19	Iniziato	Guggenheim	Buy
2020-05-19	Iniziato	JP Morgan	Overweight
2020-05-19	Iniziato	Jefferies	Buy

Mostra tutto

Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie

05:29 AM

ORIC Pharmaceuticals (NASDAQ:ORIC) Earns “Outperform” Rating from Wedbush - Defense World

Nov 14, 2024

Nov 13, 2024

Oric Pharmaceuticals Reports Strong Financial Growth and Clinical Progress - TipRanks

Nov 13, 2024

Alkeon Capital Management LLC's Strategic Acquisition in ORIC Ph - GuruFocus.com

Nov 13, 2024

Creative Planning Invests $116,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Nov 13, 2024

FMR LLC Reduces Stake in ORIC Pharmaceuticals Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

ORIC Pharmaceuticals Inc Reports Q3 2024 Net Loss of $34.6 Milli - GuruFocus.com

Nov 12, 2024

ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates - GlobeNewswire

Nov 12, 2024

ORIC Pharma Secures Major J&J, Bayer Partnerships; Reports $282M Cash Position | ORIC Stock News - StockTitan

Nov 12, 2024

Nov 08, 2024

ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at HC Wainwright - Defense World

Nov 08, 2024

Nov 06, 2024

ORICOric Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Nov 06, 2024

Nov 04, 2024

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times

Nov 04, 2024

Nov 03, 2024

Long Term Trading Analysis for (ORIC) - Stock Traders Daily

Nov 03, 2024

Nov 01, 2024

Wells Fargo Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN

Nov 01, 2024

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024

Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.00 - Defense World

Nov 01, 2024

Oct 29, 2024

Dermavant acquisition expands Organon’s dermatology portfolio - Pharmaceutical Technology

Oct 29, 2024

Oct 23, 2024

ORIC-114 shows promise in preclinical cancer study By Investing.com - Investing.com Australia

Oct 23, 2024

ORIC-114 shows promise in preclinical cancer study - Investing.com

Oct 23, 2024

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewswire

Oct 23, 2024

Oct 16, 2024

Analytical Overview: ORIC Pharmaceuticals Inc (ORIC)’s Ratios Tell a Financial Story - The Dwinnex

Oct 16, 2024